The risk for abuse was significantly lower among patients using Nucynta extended release than abuse-deterrent formulation opioids and non-abuse deterrent formulation extended-release opioids, according to data presented at PainWeek 2018.
“Safety measures intended to reduce risk of abuse/misuse include development of prescription opioids with abuse-deterrent properties as well as the use of atypical opioids that have different mechanisms of action such as tapentadol,” Jared Beaumont, MPH, from Inflexxion Inc, and colleagues wrote in the abstract.
This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc.
Heart in Diabetes
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.